ZMK
Molecule in Development
Lung Cancer
Lung cancer is one of the most common and severe types of cancer, totaling 1 in 5 cancer deaths worldwide. Three types of lung cancer may be distinguished, i.e. Small Cell Lung Cancer (SCLC), Lung Carcinoid Tumor (LCT) and Non-Small Cell Lung Cancer (NSCLC), the later being the most frequent lung cancer. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of NSCLC.
Today, clinicians use different exams to diagnose and stage the disease, combining liquid biopsy and/or brain MRI (Magnetic Resonance Imaging) and/or PET/FDG imaging. Still, PET/FDG imaging’s low specificity does not allow the characterization of tumor cells, which is an issue for clinicians when deciding which personalized targeted treatments are needed.
PET/ZMK imaging allows the visualization of EGFR (Epidermal Growth Factor Receptor) mutations in NSCLC adenocarcinoma lung cancers and can thus guide clinicians in choosing efficient targeted treatments for NSCLC adenocarcinoma lung cancers.
Population
- Mutated EGFR patients with NSCLC adenocarcinoma lung cancers
Epidemiology
- US lung cancer prevalence (5 years) : 300k, of which 80% NSCLC, of which 70% adenocarcinoma
- France lung cancer prevalence (5 years) : 60k, of which 80% NSCLC, of which 70% adenocarcinoma
Publications
- Al. Cochet et al Phase 0/1 of positron emission tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with non-small cell lung cancer (NSCLC) e24184 ASCO 2018
- Al. Cochet et al Phase 0/1 of Positron Emission Tomography (PET) imaging agent [18F]-ODS2004436 as a marker of EGFR mutation in patients with nonsmall cell lung cancer (NSCLC) OP-523 EANM 2018
